Securing exclusive domestic supply of molecular diagnostic products, including point-of-care testing (POCT) solutions
[by Kang, In Hyo] 바카라 규칙 Panagene announced on January 27 that it has recently entered into a business collaboration agreement with global biotechnology firm RocGene Technology Co., Ltd. (hereinafter referred to as RocGene) and secured exclusive distribution rights in Korea for RocGene's portfolio of point-of-care testing (POCT) products.
The agreement forms part of 바카라 규칙 Panagene's strategy to strengthen and expand its in vitro diagnostic (IVD) business. Under the collaboration, the two companies agreed to jointly advance the domestic supply and market penetration of POCT diagnostic devices and related reagents in the Korean market.
Headquartered in Beijing, China, 바카라 규칙 is a global biotechnology company specializing in molecular diagnostics as well as research equipment and integrated solutions. Established in 2016, the company develops and supplies end-to-end molecular diagnostic platforms that cover the full workflow of nucleic acid extraction, amplification, and analysis, including real-time quantitative polymerase chain reaction (real-time PCR) technologies and portable qPCR systems. 바카라 규칙 is particularly recognized for providing a broad portfolio of molecular diagnostic and life science research equipment, including POCT solutions, to the global market.
Through this partnership, 바카라 규칙 Panagene will utilize its established domestic sales and distribution network, along with its technical support capabilities, to supply RocGene's molecular diagnostic equipment and research solutions to research institutions, hospitals, diagnostic centers, and laboratories. In parallel, RocGene is expected to accelerate the global rollout of its in vitro diagnostic medical POCT devices and further strengthen its market presence in high-demand segments, such as infectious disease diagnostics and molecular biology research.
HLB Panagene reportedly entered into this agreement as part of its expansion into the in vitro diagnostics sector, determining that collaboration with RocGene, whose competitiveness has already been validated, would be more time- and cost-efficient than independently developing and commercializing new products. Furthermore, HLB Panagene expects the exclusive domestic distribution of RocGene’s products to provide a stable and recurring source of revenue.
Moreover, the company is reviewing the potential development of ‘Original Equipment Manufacturer (OEM)’ products leveraging RocGene's equipment and cartridge platform. Accordingly, the agreement is viewed as a strategic partnership that extends beyond conventional distribution deal, with the objective of broadening HLB Panagene’s in vitro diagnostic portfolio and securing future growth drivers over the mid- to long-term horizon.
"This collaboration with RocGene represents an important opportunity to further expand our in vitro diagnostic platform business. By supplying molecular diagnostic products, including POCT solutions, we aim to contribute to the growth of the Korean diagnostics market, while actively seeking additional mid- to long-term growth opportunities, such as OEM development," said Jang In-geun, CEO of HLB Panagene.
"Korea is a strategically significant market for molecular diagnostics and scientific instrumentation. Through our collaboration with HLB Panagene, we look forward to effectively introduce our competitive strengths in POCT and molecular diagnostic technologies to the Korean market and to establish a sustainable, long-term partnership," expressed Yoon Young-guk, Global Vice President of RocGene.
바카라 규칙 Panagene is a molecular diagnostics company that has grown on the basis of its proprietary peptide nucleic acid (PNA) platform technology. The company has established strong competitiveness in the diagnosis of cancer and infectious diseases and has recently expanded its business scope to include spatial biology and immunodiagnostics. Through these efforts, 바카라 규칙 Panagene is positioning itself as a comprehensive platform technology company that supports the full spectrum of precision medicine.